SpyGlass Pharma, Inc.
SpyGlass Pharma, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Surgical & Medical Instruments & Apparatus.
The next scheduled catalyst is Next quarterly earnings (projected) on October 29, 2026, a projected date rather than a confirmed one. There are 4 upcoming events on record.
Cash runway is approximately 49.4 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| October 29, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| February 28, 2027 | Evaluation of the Safety, Efficacy, Dose Response of the Bimatoprost Drug Ring System (BIM-DRS) in Pseudophakic Patients Diagnosed With Open Angle Glaucoma or Ocular Hypertension | Trial Milestone | Phase 1 |
| March 31, 2029 | Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine) | Trial Milestone | Phase 3 |
| May 31, 2029 | Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone) | Trial Milestone | Phase 3 |
Track SGP alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open SGP in the tracker| Date | Event | Type | Phase |
|---|---|---|---|
| October 1, 2026 | 8-K filed: Reg FD disclosure, Other event | Filing | — |
| August 6, 2026 | Quarterly results filed (8-K) | Earnings | — |
| May 14, 2026 | Quarterly results filed (8-K) | Earnings | — |
| March 26, 2026 | Quarterly results filed (8-K) | Earnings | — |
| March 9, 2026 | 8-K filed: Other event | Filing | — |
| February 13, 2026 | 8-K filed: Leadership change | Corporate | — |
| February 9, 2026 | 8-K filed: Leadership change, Reg FD disclosure | Corporate | — |
| January 31, 2025 | Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution | Trial Milestone | Phase 1/Phase 2 |
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.